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under the CC BY-NC-ND license (http:Summary Objectives: Recent advances in the laboratory detection of infectious diarrhoea
allow more rapid and sensitive identification of infected patients. Several commercial multi-
plex molecular panels are now available and may have significant advantages over culture
based techniques. Faster and more sensitive testing of hospitalised patients with suspected in-
fectious gastroenteritis could result in significant efficiencies in the utilisation of isolation fa-
cilities, however few studies have examined this potential benefit. We studied the potential
clinical and cost benefits of a commercially available molecular panel.
Methods: An eight-month parallel diagnostic study was conducted to measure potential eco-
nomic benefits of testing hospitalised patients with the Luminex xTAG Gastrointestinal Path-
ogen Panel (GPP) compared with conventional laboratory testing (based on a combination of
culture, microscopy and enzyme immunoassay). Laboratory testing costs and patient isolation
costs were measured or estimated for 800 patients.
Results: Although costing an additional £22,283, use of GPP could enable a reduction in isola-
tion time from 2202 to 1447 days, a saving of £66,765, which more than offsets the additional
laboratory testing costs.
Conclusion: Syndromic testing of patients against a broad panel of organisms using a multiplex
molecular panel can both improve detection rates and allow better laboratory workflowlinical Infection and Diagnostics Research (CIDR), King’s College London and Guy’s & St Thomas’ NHS
Road, London SE1 7EG, UK. Tel.: þ44 (0) 20 7188 8515; fax: þ44 (0) 20 7188 3146.
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Cost benefit analysis of multiplex gastroenteritis testing 505practices. Removing patients testing negative using this panel could result in significant pa-
tient isolation savings.
ª 2014 The Authors. Published by Elsevier Ltd on behalf of the The British Infection
Association. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Infectious gastroenteritis may be caused by a wide range of
bacteria, viruses and parasites and may be difficult to
differentiate from non-infectious causes.1,2 It is a major
burden to health services with associated socioeconomic
costs estimated to be V345 million in The Netherlands,3
A$343 million in Australia4 and Can$ 3.7 billion in Canada.5
There are an estimated 17 million cases of infectious intes-
tinal disease in the UK annually,6 however the true burden
of infection is probably significantly underestimated. It is
estimated that foodborne illness costs the UK economy
£1.5 billion annually.7
Cases of suspected infectious diarrhoea presenting to or
developing in hospitals and other health care facilities are
usually isolated in single rooms, preferably with private
bathroom, to reduce the risk of transmission. Since diar-
rhoea is a common symptom in hospitalised patients and
isolation rooms are often a scare resource, clinicians must
make pragmatic decisions regarding the use of these
facilities whilst waiting for results of laboratory testing.
Current conventional testing may be selective, reliant
on the clinician to choose the correct test, or may be
sequential, testing for one pathogen at a time. This may
create unnecessary delays or create inefficient laboratory
workflows, which are wasteful of resources. Further in-
efficiencies may result from unnecessarily isolating patients
who do not have infectious gastroenteritis. Additionally,
infectious patients who are incorrectly diagnosed as non-
infectious may be prematurely removed from isolation with
the possibility of subsequent disease transmission.
Culture dependent testing of bacterial pathogens is
slow, taking up to three days and may not be as sensitive
as molecular based methods.8e10 Multiplex molecular
panels have recently become available commercially and
have the potential to consolidate laboratory workflow,
improve diagnostic accuracy and allow more efficient use
of hospital resources.
We evaluated the healthcare economics of the Luminex
xTAG Gastrointestinal Pathogen Panel (GPP) compared to a
range of conventional laboratory testing methods including
culture and enzyme immunoassays. GPP is amultiplexedmo-
lecular test capable of simultaneously detecting adenovirus
40/41, rotavirus A, norovirus GI/GII, Salmonella spp.,
Campylobacter spp. (Campylobacter jejuni, Campylobacter
coli and Campylobacter lari), Shigella spp., (Shigella boydii,
Shigella sonnei, Shigella flexneri and Shigella dysenteriae),
Clostridium difficile, enterotoxigenic Escherichia coli
(ETEC), enterohaemorrhagic E. coli (EHEC), E. coli O157,
Yersinia enterocolitica, Vibrio cholera, Giardia lamblia,
Entamoeba histolytica and Cryptosporidium spp. (Crypto-
sporidium parvum and Cryptosporidium hominis). The assay
uses the proprietary Luminex xTAG technology and plat-
form to detect multiple targets in the same sample.Materials and methods
An eight-month parallel evaluation study was conducted at
Guy’s and St. Thomas’ NHS Foundation Trust, a 1100 bed
academic teaching hospital in central London between
November 2011 and July 2012. This was designed to assess
the feasibility, clinical utility and acceptability of using GPP
to detect infectious gastroenteritis in unselected samples
from hospitalised patients sent to our laboratory, and the
findings are reported elsewhere.11 The economics of a
range of conventional testing methods (including selective
culture, enzyme immunoassays and molecular testing, see
Table 1.)11 were compared with testing by GPP in terms
of; diagnostic costs (the relative costs of the conventional
and GPP methods) and patient isolation costs (the potential
benefits of reducing time spent in isolation).
Protocol approval was obtained from the London City &
East Research Ethics Committee. Patients admitted to
hospital who developed diarrhoea and/or vomiting were
placed in single rooms with private bathroom and kept in
isolation until at least 48 h following return to normal bowel
habit. Cross-transmission between hospitalised patients
with gastrointestinal parasite infection is rare, so for the
purposes of this study these patients were defined as having
non-communicable gastroenteritis and standard infection
control precautions were implemented. These patients
were not required to remain in single room isolation in
accordance with CDC guidelines.12
Clinicians investigated all cases of diarrhoea using a range
of conventional testing methods according to their usual
clinical practice and hospital infection control guidelines.
Requesting bacterial culture on patients with hospital-
associated diarrhoea is discouraged but not prevented.
Infection control guidelines recommend that symptomatic
patients (i.e. passage of 3 or more liquid stools within 24 h)
considered likely tobe infectious inaetiology (that is,without
any otherobvious causes such asmedicationsor inflammatory
bowel disease), should be placed in single rooms. Conven-
tional testingwas performed 7 days perweek. Clinicianswere
unable to request a GPP test directly, instead; whenever a
request for a conventional test was received, a GPP test was
automatically triggered with the limitation that only oneGPP
test was performed per five-day period (defined as a single
episode). Clinicians were advised to act on negative GPP
results and remove the patient from isolation. For laboratory
operational reasons, GPP samples were batched for testing
commencing at 4pm Monday to Thursday with results avail-
able at 3pm the following day. On Fridays samples were
tested earlier with results available on the evening of the
same day or early Saturday morning. Samples received on
Saturday and Sunday were not tested. Results were commu-
nicated electronically to requesting clinicians, with positive
results telephoned out by an infectious diseases physician, as
per the standard for conventional tests.
Table 1 Conventional testing methods, number of tests performed and associated costs.
Conventional test targets Conventional test methodsa Number of initial
tests performed
Number of
repeat tests
performed
Cost per
test (£)b
Total
costs (£)b
Clostridium difficile Glutamate Dehydrogenase Enzyme
Immunoassay (C. diff Chek-60;
TechLab, Balcksburg, VA, USA)
then GenXpert PCR (Cepheid,
Sunnyvale, CA, USA)
513 58 26.05 14,875
Norovirus Enzyme Immunoassay (Ridascreen
3rd generation assay; R-Biopharm,
Darmstadt, Germany)
549 57 18.68 11,320
Adenovirus and Rotavirus Combined immunochromatographic
test (Ridaquick Rotavirus/Adenovirus
combi; R-Biopharm, Darmstadt,
Germany)
61 8 7 484
Campylobacter, Salmonella,
Shigella, and E. coli O:157
Culture on selective and chromogenic
agars followed by matrix-assisted
laser desporption/ionization-time
of flight mass spectrometry and/or
basic serotyping
541 25 11.30 6396
Giardia, Entamoeba
histolytica and
Cryptosporidium
Light or fluorescent microscopy 80 4 10.53 885
Total 1744 152 33,960
a Full testing methodology in Halligan et al.
b Costs include all consumables, labour and overheads.
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compare groups of patients tested with either conventional
methods or GPP. Instead, both testing methods were
performed in parallel so that diagnostic accuracy could be
measured, this is reported elsewhere.11 Consequently, it
was not possible to infer that decisions on isolation of pa-
tients were made as a result of any testing pathway alone.
Results from conventional and GPP testing became avail-
able at different times and these decisions would in reality
have been influenced by the availability of both testing
methods. Assumptions were made on the likely length of
isolation for patients testing negative by GPP (based on
actual turnaround time of the laboratory test plus local
knowledge of the average time taken to deisolate patients
after receipt of negative results), however this may have
underestimated the potential economic savings attribut-
able to GPP.
The analysis is written from the perspective of the NHS
and does not consider costs associated with false positive
and false negative results, treatment costs and treatment
outcomes, the economic value of preventing outbreaks
within hospital which result from failing to isolate when
necessary, or preventing hospital admissions for gastroen-
teritis patients who did not require isolation.
The number of conventional tests performed, patient
outcomes and the actual total number of isolation days
per patient were measured. The Isolation costs under the
conventional testing pathway are based on the actual
patient isolation days observed during the study. Data
were also collected for the GPP tests and results plus the
estimated isolation time for each patient if the GPPresults had been the sole source of reference for deci-
sion-making.
The economic analysis compares the actual cost of
conventional testing and actual number of isolation days
observed vs. the costs of GPP testing and theoretical
number of isolation days based solely on GPP results. The
costs of GPP testing include any confirmatory testing by
conventional assays (i.e. costs of culture and antimicrobial
sensitivity testing for Campylobacter, Salmonella, Shigella
and E. coli O157 and costs of confirmatory toxin enzyme-
immunoassay for C. difficile).
Patients with ongoing symptoms despite negative con-
ventional tests were permitted to be re-tested by further
conventional tests at the physician’s discretion. Due to the
improved sensitivity and negative predictive value of the
GPP test, patients were permitted to be tested only once in
any five day period.Results
Isolation data
Patient tracking data were available for a total of 913
patient episodes, however 113 (14%) patients were not
removed from isolation despite a negative GPP. This was
due to a variety of reasons including colonisation with MRSA
or other multi-drug resistant organisms, lack of alternative
beds and dignity and safeguarding concerns. These patient
episodes were not included in the isolation analysis since
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affected their time in isolation.
Conventional testing pathway
Testing outcomes for patients tested using the conventional
testing pathway and the simulated GPP pathway are
summarised in Figs. 1 and 2.
Under the conventional testing pathway a total of 409
(51%) of symptomatic patients were isolated whist awaiting
test results, of which 81 had one or more agents of
infectious gastroenteritis detected. All of these patients
had a communicable cause requiring continued isolation. A
total of 328 of the isolated patients did not have an agent of
infectious gastroenteritis detected; symptoms resolved in
314 of these patients and they were removed from
isolation. Symptoms persisted in 14 of these patients and
they were retested and alternative causes considered. In all
but one case where norovirus was subsequently detected,
no infectious cause of diarrhoea was identified.
Of the 391 patients who were not isolated, an agent of
infectious gastroenteritis was detected in 20. Nineteen of
these patients were infected with a communicable agent
and were isolated and treated, the remaining patient had a
non communicable cause and remained non-isolated. 371 of
the non-isolated patients did not have an agent of infec-
tious gastroenteritis detected; symptoms persisted in 42 ofFigure 1 Outcomes under the conventional testing pathway. 1Inf
were considered non communicable infections and patients were nthese patients and they were retested and alternative
causes considered. Symptoms resolved in the remaining
329 patients. In total 409 patients were isolated for a total
of 2116 days under the conventional testing pathway. See
Table 2.
Simulated GPP testing pathway
Under the GPP testing pathway the same number of
symptomatic patients were isolated (409), however detec-
tion rates were higher with 152 patients having an agent of
infectious gastroenteritis detected (an increase of 37%). Of
those, 141 had a communicable cause and were kept
isolated. 257 of the isolated patients did not have an agent
of infectious gastroenteritis detected; symptoms were
assumed to have resolved in all of these patients and they
were removed from isolation. Fig. 2 summarises the GPP
testing pathway outcomes.
Of the 391 patients who were not isolated, an agent of
infectious gastroenteritis was detected in 48, 40 of these
were with a communicable agent and were isolated and
treated; the remaining 8 patients had non-communicable
causes and remained non-isolated. 343 of the non-isolated
patients did not have an agent of infectious gastroenteritis
detected and symptoms were assumed to have resolved.
The actual days observed in isolation for the 191
patients with communicable infectious gastroenteritisection with Giardia, Cryptosporidium or Entamoeba histolytica
ot isolated.
Figure 2 Outcomes under the simulated GPP testing pathway. 1Infection with Giardia, Cryptosporidium or Entamoeba histoly-
tica were considered non communicable infections and patients were not isolated.
508 S.D. Goldenberg et al.were 691. Each of the 11 patients who had non-
communicable infectious gastroenteritis was assumed to
spend 2 days in isolation before being removed (a total of
22 days for this group).
Similarly patients who were presumptively isolated but
did not have an agent of infectious gastroenteritis detected
were assumed to spend 2 days each in isolation beforeTable 2 Patient isolation data under the conventional and sim
Patient status Conve
Total
patien
Communicable IG, patient isolated (a) 81
Non-communicable IGa detected, patient isolated (b) 0
IG not detected, patient isolated (c þ d) 328
Communicable IG detected, patient not isolated (e) 19
Non-communicable IGa detected, patient not isolated (f) 1
IG not detected, patient not isolated (g þ h) 371b
Total (a to h) 800
IG Z infectious gastroenteritis.
a Infections with Giardia, Cryptosporidium or Entamoeba histolytica
required.
b 42 patients with ongoing symptoms were assumed to be remain in
c Estimated total isolation days cased on total isolation duration ofbeing removed (a total of 257 patients and 514 isolation
days). The 40 patients with communicable infectious
gastroenteritis but who were not presumptively isolated
were subsequently moved into isolation; this was a total of
220 days.
The total isolation time for the GPP testing pathway was
1447 days, 755 days less than the conventional testingulated GPP testing pathways.
ntional testing pathway GPP testing pathway
ts
Actual observed
isolation days
Total
patients
Actual observed or
estimated isolation days
446 141 691
0 11 22c
1703 257 514c
0 40 220
0 8 0
53 343 0
2202 800 1447
were considered non-communicable and patient isolation was not
isolation with a total isolation time of 53 days.
2 days per patient.
Table 3 Economic analysis of conventional and GPP
testing pathways.
Conventional testing pathway
Total number of isolation days 2202
Total isolation costs £194,723
Total laboratory testing costs £33,960
Total costs £228,683
GPP testing pathway
Total number of isolation days 1447
Total isolation costs £127,958
Total GPP laboratory testing costs £55,104
Total confirmatory testing costsa £1139
Total laboratory testing costs £56,243
Total costs £184,201
Difference (GPP testing pathway e
conventional testing pathway)
Total number of isolation days 755
Total isolation costs £66,765
Total laboratory testing costs £22,283
Total costs £L44,482
a Includes confirmatory culture and antimicrobial susceptibil-
ity testing for 51 samples positive by GPP for Campylobacter,
Salmonella, Shigella and E. coli O157 (£11.30 per test) plus
confirmatory toxin A/B enzyme-immunoassay for 45 samples
positive by GPP for C. difficile (£12.50 per test).
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GPP testing pathway.
Testing results and costs
Performance characteristics of the GPP were not taken into
consideration in this study and all GPP tests were assumed
to be 100% accurate, this may not be the case, however
several studies have reported improved detection rates
using GPP11,13,14 and other commercially available molecu-
lar panels.15e17
GPP identified an additional 81 patients with infectious
gastroenteritis compared with conventional testing,
including 21 patients who had not been presumptively
isolated.
A total of 1744 initial tests and 152 repeat tests were
performed at a cost of £33,960. With unrestricted access to
all conventional tests, clinicians ordered a mean of 4.5
tests per patient episode, which includes repeated testing
for the same pathogen(s), which occurred for 7% of patients
overall. Only one GPP test was permitted per five-day
patient episode. The cost of a GPP test was £68.88.
Confirmatory testing was also costed for culture and
antimicrobial susceptibility testing of Campylobacter, Sal-
monella, Shigella and E. coli O157 (£11.30 per test) and
confirmatory toxin A/B testing for C. difficile positives
(£12.50 per test). This resulted in a total testing cost of
£56,243 for all 800 patient episodes.
Table 1 summarises the total number of conventional
tests performed and their associated costs, calculated us-
ing an activity based costing algorithm and including all
equipment, consumables, labour and overheads.
Cost benefit analysis
The incremental cost of providing and servicing the addi-
tional space with single beds in single room isolation
compared to open wards was estimated at £88.43/day.18
A reduction in the number of days a patient spends in isola-
tion results in an economic saving and increases capacity
for other infectious patients. The GPP testing pathway re-
sulted in the potential to save 755 isolation days at a cost
of £66,765.
The overall costs for laboratory testing of patients using
GPP (£56,243) was more than that of conventional testing
costs (£33,960). However, the reduction in isolation costs
(1447 days for GPP testing pathway vs. 2202 days for the
conventional testing pathway) generated savings of £66,765
for the GPP testing pathway, which offset the additional
laboratory testing costs and produced an overall cost saving
of £44,482. The economic analysis of both testing pathways
are summarised in Table 3.
Sensitivity analysis
Since the economic benefit of the GPP test is contingent on
removing patients testing negative from isolation, any
change in the isolation time will affect the cost benefit
analysis. A sensitivity analysis around the time spent in
isolation was conducted, varying the time spent from one
to three days, in increments of half a day. In all cases therewas a net saving under the GPP testing pathway. Table 4
shows how the time in isolation affects the economic
benefit of using the GPP testing pathway.
Breakeven analysis
The breakeven analysis is designed to indicate the degree
to which savings in isolation days need to be achieved to
cover the additional GPP diagnostic costs. The breakeven
analysis converts the incremental cost of GPP diagnosis into
the equivalent number of isolation days that would need to
be reduced for the net economic outcome to be £0, i.e. the
costs equal the savings. The analysis found that the overall
breakeven point associated with implementing GPP is a
reduction of 252 isolation days (11.4%). See Table 5.
Discussion
Despite significant additional laboratory testing costs, the
GPP testing pathway could result in overall savings due to a
significant reduction in isolation days required (a reduction
of 755 days at a saving of £66,765) over the course of this
study). The overall saving under the GPP testing pathway
was £44,482.
These savings are dependent upon being able to remove
patients with negative GPP tests from isolation. The
turnaround time of the GPP test must therefore be faster
than the turnaround time for conventional testing. This was
measured in our previous study, which found the median
turnaround time for conventional testing ranged from 17.3
to 66.5 h and the median GPP turnaround time to be
41.8 h.11 Others have reported faster turnaround times for
the GPP test,14 however it is not clear if sample collection
Table 4 Sensitivity analysis. The time in isolation was altered from one to three days in increments of half a day to estimate
the overall effect on isolation savings.
Isolation days 3.0 days 2.5 days 2.0 days 1.5 days 1.0 days
Total isolation days GPP testing
pathway
1715 1581 1447 1313 1179
Total isolation cost under GPP
testing pathway
£151,602 £139,754 £127,944 £116,057 £104,209
Total laboratory testing costs
for GPP
£56,243 £56,243 £56,243 £56,243 £56,243
Total costs for GPP testing
pathway
£207,845 £195,997 £184,187 £172,300 £160,452
Total costs for conventional
testing pathway
£228,661 £228,661 £228,661 £228,661 £228,661
Net savings using GPP testing
pathway
£20,816 £32,664 £44,474 £56,361 £68,209
Table 5 Break-even analysis of the GPP testing pathway.
Cost of GPP laboratory testing £56,243
Cost of conventional laboratory testing £33,960
Additional cost of GPP laboratory testing £22,283
Equivalent days in isolation at £88.43 per day 252
Total isolation days under conventional testing
pathway
2202
Percentage reduction in isolation days needed
to break-even
11.4%
510 S.D. Goldenberg et al.and transportation time were included in the total turn-
around time in this study. These measurements are essen-
tial to include when assessing the potential clinical
impact. The economic benefit of using the GPP testing
pathway was maintained even if the average time in isola-
tion was increased to three days.
Molecular testing may not be able to completely replace
conventional culture based testing, since it does not yield
antimicrobial susceptibility data. Positive tests should be
confirmed with culture, which also provides valuable
epidemiological information for public health purposes
e.g. strain typing.
Our study did not attempt to measure the risk of
transmitting an undetected pathogen in those patients
removed from isolation after receiving a negative GPP
test. Sapovirus and astrovirus are not included on the GPP
panel yet have been implicated in several hospital out-
breaks.19e21 Ultimately clinicians and other decision
makers must have clinical confidence in the diagnostics
that laboratories provide, in order to make individual pa-
tient management decisions. A trusted and highly accurate
test may ultimately reduce unnecessary repeat testing of
patients.
In our institution samples submitted from hospitalised
patients represent just over 30% of the total samples
submitted to our laboratory. The remaining samples origi-
nate from outpatient clinics and local general practi-
tioners, and the advantage in terms of cost-effectiveness
may be more limited in this group.
A significant limitation of the study was the parallel
testing design, thus it was not possible to measure isolationtimes resulting from either conventional tests or GPP alone.
In all likelihood the measures were a composite of both GPP
and conventional tests (since some conventional tests had a
shorter and others a longer turnaround time that GPP).
In addition to the outlined potential economic benefits,
and the previously described improved sensitivity and
turnaround times compared with some conventional testing
methods, there is also the potential to consolidate labora-
tory workflow, allowing a single specimen to be tested for
multiple targets.
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